# Alligator Bioscience

Source: https://onco.cc/companies/alligator-bioscience/  
OnCo record `alligator-bioscience` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alligator Bioscience is a Swedish biotech that makes antibodies to switch on the immune system inside tumours; its CD40 agonist mitazalimab, given with chemotherapy, shrank tumours in 42 per cent of people with untreated metastatic pancreatic cancer in a single-arm trial, which cannot show whether it improves survival.

## Summary

Alligator Bioscience, based in Lund, develops tumour-directed immunotherapies from its FIND antibody library and RUBY bispecific format. Mitazalimab (ADC-1013), a CD40 agonist that primes dendritic cells and T cells, was tested with modified FOLFIRINOX in the single-arm phase 1b/2 OPTIMIZE-1 trial in untreated metastatic pancreatic cancer, which met its primary endpoint with a confirmed response rate of 42.1 per cent and reported median overall survival of 14.9 months; with no control group it cannot show whether mitazalimab improves survival, and the authors plan a randomised confirmatory trial. ATOR-4066 is a Neo-X-Prime bispecific against CD40 and CEACAM5.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Alligator Bioscience AB; STO:ATORX
- Tags: drug-maker
- HQ: Lund
- Type: biotech
- Website: https://www.alligatorbioscience.com/
- Ticker: STO:ATORX

## Sources

- Official website: https://www.alligatorbioscience.com/
- OPTIMIZE-1: mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer, single-arm phase 1b/2 (Lancet Oncol 2024): https://doi.org/10.1016/S1470-2045(24)00263-8

## Connected records

- drugs: [Mitazalimab](https://onco.cc/drugs/mitazalimab/)
- trials: [Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients](https://onco.cc/trials/nct04888312/)

---
JSON: https://onco.cc/api/v1/entities/alligator-bioscience.json